# PET/MRI Evaluation of Cardiac Amyloid

> **NCT03119558** · EARLY_PHASE1 · COMPLETED · sponsor: **Stanford University** · enrollment: 9 (actual)

## Conditions studied

- Cardiac Amyloidosis

## Interventions

- **DRUG:** 18F-Florbetaben (Neuraceq®) PET/MRI

## Key facts

- **NCT ID:** NCT03119558
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-26
- **Primary completion:** 2018-08-23
- **Final completion:** 2018-08-28
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2019-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03119558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03119558, "PET/MRI Evaluation of Cardiac Amyloid". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03119558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*